Uncover key drivers, emerging technologies, and competitive movements shaping the shingles vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Market Size Of The Shingles Vaccine Industry By 2029?

The shingles vaccine market has seen substantial growth over recent years. It is anticipated to expand from $4.82 billion in 2024 to $5.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.0%. This historical expansion is largely due to factors such as an expanding elderly demographic, increased public understanding of vaccine advantages, improvements in healthcare infrastructure and immunization schemes, a greater occurrence of immunocompromised states, and the growing acceptance of advanced, more potent vaccines.

The shingles vaccine market size is anticipated to undergo rapid expansion in the upcoming years, projected to reach $9.58 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 14.6%. This growth during the forecast period is primarily driven by factors such as expanding government reimbursement and beneficial pricing policies, a rise in physician recommendation rates, an increased public health focus on adult vaccination, growing investments in research and development along with product diversification, and improvements in global supply chains and cold-chain capacity. Significant trends expected during this period include advances in recombinant vaccine technology, enhancements in adjuvant systems, the integration of shingles vaccination into standard adult immunization schedules, the adoption of digital health platforms for tracking vaccines, and progress in vaccine formulations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Factors Are Steering Growth In The Shingles Vaccine Market?

The expanding presence of vaccination initiatives is projected to boost the future expansion of the shingles vaccine market. These initiatives are structured public health efforts aimed at systematically delivering vaccines to communities to prevent the spread of infectious diseases. The rise in vaccination programs is driven by heightened consciousness regarding preventive healthcare, prompting more individuals to seek vaccination for disease prevention. Vaccination programs boost the uptake of shingles vaccines by improving public understanding and availability, making them suitable for older adults and at-risk demographics. They mitigate the danger of shingles and its associated complications through encouraging prompt and extensive immunization, thereby enhancing overall public well-being. For example, in July 2025, the World Health Organization, a Switzerland-based Intergovernmental organization, reported that the coverage for the first dose of human papillomavirus (HPV) vaccine in girls rose from 27% in 2023 to 31% in 2024. Consequently, the growing prevalence of vaccination programs is fueling the growth of the shingles vaccine market.

Which Segment Accounts For The Largest Share In The Shingles Vaccine Market?

The shingles vaccine market covered in this report is segmented

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine

Which Long-Term Trends Will Play A Crucial Role In The Shingles Vaccine Market?

Key companies within the shingles vaccine market are prioritizing the development of advanced vaccine formulations, such as recombinant adjuvanted vaccines, to bolster immune responses and deliver enduring protection against shingles. Recombinant adjuvanted vaccines work by combining laboratory-engineered viral proteins with substances known as adjuvants, which serve to intensify the body’s immune defense for superior and longer-lasting immunity. As an illustration, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, a vaccine specifically for shingles. Shingrix is a non-live, recombinant adjuvanted subunit vaccine given intramuscularly in two doses to adults aged 50 and above, designed to avert shingles (herpes zoster) and its related severe condition, post-herpetic neuralgia. This highly potent vaccine provides over 90% protection against shingles, ensuring a strong and sustained immunity that persists for at least 10 years, even among older adults and those with compromised immune systems.

Who Are The Dominant Players In The Shingles Vaccine Market Today?

Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

What Regional Factors Are Accelerating Growth In The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2025, By The Business Research Company

Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Foldable Houses Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Excavation And Demolition Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/excavation-and-demolition-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model